Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according to discussion at ESMO 2020. A phase 3 study, presented at the ESMO Virtual Congress 2020, randomised 529 women to either sacituzumab or their physician’s chemotherapy of choice. The drug is a first-in-class conjugate of ...
New first-in-class treatment option for triple negative breast cancer
By Mardi Chapman
24 Sep 2020